Search results
Showing 226 to 240 of 243 results for prescriptions
More than 20,000 people benefitting from innovative migraine pills recommended by NICE
A new type of tablet specifically designed to prevent migraine is transforming lives across England, with the number of people being prescribed these medicines more than tripling in just one year.
This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes
Methods for the development of NICE public health guidance (third edition) (PMG4)
This manual describes the methods used by the Centre for Public Health Excellence (CPHE) in NICE to develop and update public health guidance
Major changes to type 2 diabetes treatment could save thousands of lives
New guidance means millions of people will get access to medicines that protect the heart and kidneys, while NHS savings of £560 million from using generic dapagliflozin can be reinvested elsewhere in NHS care.
New hope for people with breathing condition, COPD, as NICE approves innovative treatment
Breakthrough therapy reduces flare-ups by almost a third and could ease pressure on NHS hospitals.
New age-based blood test thresholds recommended by NICE will help GPs catch ovarian cancer earlier
More women with ovarian cancer could be diagnosed earlier under proposed new NICE guidance that replaces a one-size-fits-all blood test threshold with personalised, age-based criteria.
Our landmark review demonstrates a new approach to keeping NHS care up-to-date and could benefit thousands of adults with metastatic prostate cancer.
Recommendations in NICE’s type 2 diabetes guideline update, published today, will enhance the use of SGLT-2 inhibitors in primary care and address these health inequalities.
recent analysis showing significant disparities in SGLT-2 inhibitor prescriptions for people with type 2 diabetes in England. We also...
Biggest shake-up in type 2 diabetes care in a decade announced
Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority clinical pathways described in the 10-Year Health Plan for the NHS.
Contraception: LARC for people using emergency contraception (IND149)
This indicator covers the percentage of women, on the register, prescribed emergency hormonal contraception 1 or more times in the preceding 12 months by the contractor who have received information from the contractor about long acting reversible methods of contraception at the time of or within 1 month of the prescription. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomesThis indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM115
Four innovative tests for diagnosing UTIs could help in the fight against antimicrobial resistance
NHS may use innovative tests which may help people with a urinary tract infection (UTI) receive the correct course of antibiotics more quickly.
Decision aid to guide discussions on sleeping pill prescriptions
A patient decision aid on medicines associated with dependence or withdrawal symptoms has been published
Angela sets out to understand some of the challenges, benefits and considerations of setting up and running a virtual ward, from the perspective of teams on the front lines.
NICE reaches important milestone in the UK's efforts to tackle antimicrobial resistance.
Two new antimicrobial drugs are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model.